| Outcome Measures: |
Primary: Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961, Cmax was the maximum observed plasma concentration and was directly observed from data., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961, AUCinf was defined as area under the plasma concentration-time curve from time zero to infinity., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961, AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Fraction Unbound (fu) of Plasma PF-06882961, Fu was defined as fraction of unbound drug in plasma., 0 (pre dose), 4 hours (post dose) on Day 1 | Secondary: Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961, Cmax,u was defined as maximum observed concentration of unbound drug., 0 (pre dose), 4 hours (post dose) on Day 1|Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961, AUCinf,u was defined as unbound area under the plasma concentration-time profile from time zero extrapolated to infinite time., 0 (pre dose), 4 hours (post dose) on Day 1|Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961, AUClast,u was defined as unbound area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration., 0 (pre dose), 4 hours (post dose) on Day 1|Apparent Clearance (CL/F) of Plasma PF-06882961, Apparent Clearance After Oral Dose (CL/F) was defined as apparent clearance after oral dose on the last day of treatment period., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961, CLu/F was defined as apparent clearance of unbound drug., 0 (pre dose), 4 hours (post dose) on Day 1|Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961, Vz/F was defined as apparent volume of distribution., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Unbound Vz/F (Vz,u/F) of Plasma PF-06882961, Vz,u/F was defined as apparent volume of distribution of unbound drug., 0 (pre dose), 4 hours (post dose) on Day 1|Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961, Tmax was defined as time to maximum observed concentration. Observed directly from data as time of first occurrence., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Terminal Elimination Half-Life (T1/2) of Plasma PF-06882961, Plasma terminal elimination half-life (T1/2) is the time measured for the plasma concentration to decrease by one half at the terminal phase., 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities), An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event (TEAE) means event between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of death; inpatient hospitalization; life-threatening experience; disability; congenital anomaly or deemed significant for any other reason., From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)|Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality), Laboratory test abnormalities included hematology, chemistry and urinalysis., From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)|Number of Participants With Abnormal Vital Signs, The vital signs were measured included pulse rate (beats/min) and blood pressure (mmHg)., From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)|Number of Participants With Abnormal Electrocardiograms (ECGs), ECG parameters included QTCF, PR interval, and QRS interval., From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
|
